Cochrane · intervention · CD013628
Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol‐generating procedures (AGPs) on patients without suspected or confirmed COVID‐19 infection
Burton, MJ, Clarkson, JE, Goulao, B, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Full textEvery question was extracted from the full review (methods and results), not only its Summary of Findings table.
Questions
6
current version
GRADE rated
0
No studies
6
Included studies
0
as reported
No studies 6 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs); Healthcare workers (HCWs) treating them; Any healthcare setting | Insufficient data |
| Intervention | Antimicrobial mouthwash (any type, any concentration); Antimicrobial nasal spray (any type, any concentration); Mouthwash and/or nasal spray in combination; Delivered to patient and/or HCW before and/or after an AGP | Insufficient data |
| Comparison | No treatment; Saline; Water | Insufficient data |
| Outcomes | Incidence of symptomatic or test-positive COVID-19 infection in HCWs or patients (primary); Anosmia or disturbance in sense of smell (primary); COVID-19 viral content of aerosol (secondary); Change in COVID-19 viral load at site(s) of irrigation (secondary); Changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx (secondary); Allergy, irritation/burning of oral or nasal mucosa, staining, accidental ingestion (secondary) | Insufficient data |
| Study designs | Randomised controlled trials (RCTs); Quasi-RCTs; Non-randomised controlled trials; Prospective cohort studies; Retrospective cohort studies; Cross-sectional studies; Controlled before-and-after studies | Insufficient data |
| Timing | Primary outcomes assessed at a minimum of 2 weeks; no minimum follow-up for secondary outcomes; no minimum study duration | Insufficient data |
Search date: 2020-06. Databases: CENTRAL (Cochrane Central Register of Controlled Trials); Ovid MEDLINE; Ovid Embase; WHO COVID-19 Global literature on coronavirus disease; Cochrane COVID-19 Study Register
Questions and results
Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to the patient or HCW before and/or after an AGP vs No treatment or saline or water
Population: Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs), and the healthcare workers (HCWs) treating them
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Other adverse events: allergy, irritation/burning of nasal, oral or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding), long-term staining of mucous membranes or teeth, accidental ingestion | No data available (no included studies) | NR | No studies |
Change in COVID-19 viral load at site(s) of irrigation | No data available (no included studies) | NR | No studies |
Anosmia (or disturbance in sense of smell) Assessed at a minimum of 2 weeks | No data available (no included studies) | NR | No studies |
Other adverse events: changes in microbiome in oral cavity, nasal cavity, oro- or nasopharynx | No data available (no included studies) | NR | No studies |
Incidence of symptomatic or test-positive COVID-19 infection in HCWs or patients Assessed at a minimum of 2 weeks | No data available (no included studies) | NR | No studies |
COVID-19 viral content of aerosol | No data available (no included studies) | NR | No studies |